SCHEMBL3217007

SCHEMBL3217007

N#Cc1cccc(Cl)c1C=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.61
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
TERT O14746 1/20 0.42
GRIA1 P42261 1/20 0.42
CACNG8 Q8WXS5 1/20 0.42
DYRK1A Q13627 1/20 0.41
SLC22A12 Q96S37 4/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
HSP90AA1 P07900 1/20 0.36
KDM4E B2RXH2 2/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.34
MCL1 Q07820 1/20 0.34
TRPV4 Q9HBA0 1/20 0.34
HTT P42858 2/20 0.34
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6903631 0.85 ALDH1A1 (0.42) ALDH1A1MEN1KMT2ATDP1TERT
SCHEMBL7527729 0.78 ALDH1A1 (0.44) ALDH1A1MEN1KMT2ATDP1KDM4E
SCHEMBL96214 0.78 ALDH1A1 (1.00) ALDH1A1MEN1KMT2ATDP1HSP90AA1
SCHEMBL28162291 0.76 DYRK1A (0.41) ALDH1A1MEN1KMT2ATDP1DYRK1A
SCHEMBL29954526 0.76 TSHR (0.54) ALDH1A1MEN1KMT2ATDP1CA1
SCHEMBL29955549 0.76 ERN1 (0.38) ALDH1A1MEN1KMT2ATDP1CA1
SCHEMBL29953764 0.76 ERN1 (0.41) ALDH1A1MEN1KMT2ATDP1CA1
SCHEMBL28738488 0.76 TSHR (0.54) ALDH1A1MEN1KMT2ATDP1CA1
SCHEMBL7530450 0.76 ERN1 (0.38) ALDH1A1MEN1KMT2ATDP1CA1
SCHEMBL28806185 0.75 ALDH1A1 (0.94) ALDH1A1MEN1KMT2ATDP1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107382820-A A kind of synthetic method of 3 arylisoindole derivative 常州大学 2017-11-24 CN claimed
CN-105111217-A Method for synthesizing isoindole dihyroquinazoline derivative UNIV CHANGZHOU 2015-12-02 CN claimed
CN-104876850-A Isoindolinone derivative synthesis method UNIV CHANGZHOU 2015-09-02 CN claimed
CN-116283810-B Preparation method of isoxazole compound 上海麦克林生化科技股份有限公司 2024-04-19 CN disclosed
CN-116283810-A Preparation method of isoxazole compound 上海麦克林生化科技股份有限公司 2023-06-23 CN disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
EP-2432776-B1 METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS UNIV LAVAL (CA) 2019-09-11 EP disclosed
CN-107382820-A A kind of synthetic method of 3 arylisoindole derivative 常州大学 2017-11-24 CN disclosed
CN-104876850-B A kind of synthetic method of isoindolinone derivatives 常州大学 2017-09-08 CN disclosed
CN-105111217-B A kind of synthetic method of iso-indoles dihydroquinazoline derivatives 常州大学 2017-07-14 CN disclosed
US-9315521-B2 Pyrimidines as novel therapeutic agents UNIVERSITé LAVAL (CA) 2016-04-19 US disclosed
CN-104876850-A Isoindolinone derivative synthesis method UNIV CHANGZHOU 2015-09-02 CN disclosed
US-20150225423-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITé LAVAL (CA) 2015-08-13 US disclosed
US-20150225423-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITé LAVAL (CA) 2015-08-13 US disclosed
US-9040538-B2 Pyrimidines as novel therapeutic agents UNIVERSITE LAVAL (CA) 2015-05-26 US disclosed
US-9040538-B2 Pyrimidines as novel therapeutic agents UNIVERSITE LAVAL (CA) 2015-05-26 US disclosed
US-20100298336-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITE LAVAL (CA) 2010-11-25 US disclosed
US-20100298336-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITE LAVAL (CA) 2010-11-25 US disclosed
WO-2010132999-A1 METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS CHLORION PHARMA, INC. (CA) 2010-11-25 WO disclosed
WO-2010009047-A1 PYRIDONE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298336-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS TYMS, P2RX2, TYMP ALDH1A1 577/4885MEN1 4378/4885KMT2A 3590/4885
US-20150225423-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS TYMS, P2RX2, TYMP ALDH1A1 577/4885MEN1 4378/4885KMT2A 3590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.